Preventing invasive fungal
infections.
Article Tools
Add to My Bookmarks
Adds Article to your Entrepreneur Assist Bookmark page.
The FDA has approved Kenilworth, New Jersey-based Schering-Plough
Corporation's Noxafil (posaconazole) oral suspension, indicated to
prevent invasive Aspergillus and Candida infections in patients 13 years
of age and older who are severely immunocompromised. The drug is the
only antifungal agent approved for the prevention of infections caused
by the Aspergillus species.
COPYRIGHT 2006 Medicom International,
Inc. Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
Copyright 2006, Gale Group. All rights
reserved. Gale Group is a Thomson Corporation Company.
NOTE: All illustrations and photos have been removed from this article.
Browse by Journal Name: